Date of Abstract presentation11th December 2023
IndicationsDiffuse large B-cell lymphoma (DLBCL)
Abstract Number4496
Abstract typePoster

Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-third of all diagnosed cases. Over two-thirds of DLBCL patients face either non-response or relapse after second-line treatment. Those experiencing relapse or inadequate response to initial interventions confront a scarcity of conventional treatment choices that offer sustained remission, leading to a median life expectancy of approximately six months. This underscores a pressing demand for innovative therapies to address this critical unmet medical need. As per the results presented at the ASH 2023 conference, there were 26 patients evaluated for efficacy, and the overall response rate (ORR) reported was 42%, with 19% of patients achieving a complete response (CR). Moreover, the median duration of response was 7.5 months. Apart from that, the ORR and CR rate was greater for patients in the 0.4 mg arm compared to the 0.2 arm.

In terms of safety assessment, neutropenia emerged as the predominant treatment-emergent adverse event (TEAE) of any grade, affecting 50% of the participants. Among the reported serious adverse events, pneumonia, and pyrexia were the only occurrences observed in more than one patient, each reported in two cases. Throughout the study, four deaths occurred during treatment, with one related to the study treatment.

KOL Insights

“Golcadomide is a novel, oral CELMoD agent representing one of several compelling assets generated from our differentiated targeted protein degradation research platform. “In the studies being presented at ASH 2023, golcadomide has shown potential warranting further evaluation in patients with first-line and previously treated large B-cell lymphomas. We are encouraged by the growing body of evidence for this purposefully designed lymphoma agent as we continue toward a registrational program.” –Expert Opinion.


The combination of oral golcadomide therapy with rituximab demonstrated encouraging effectiveness in patients with R/R DLBCL who had undergone extensive prior treatments.

Refer to the Related Reports for More In-depth Insights –